BMS-986192
mAbexperimentalImaging agent
Clinical trial activity
3 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started May 22, 2017 (NCT03520634)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Programmed cell death 1 ligand 1INHIBITOR
CD274 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
- Imaging
- 18-fluorine
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05408871 | Phase 1 | Nov 30, 2022 | National Cancer Institute (NCI), Yale University |
| NCT03564197 | N/A | Oct 1, 2018 | Bristol-Myers Squibb, Netherlands Cancer Institute |
| NCT03520634 | N/A | May 22, 2017 | University of Groningen |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bristol-Myers Squibb | For profit | 1 | 0 | 1 | 2018 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2022 |
| Netherlands Cancer Institute | Academic/Hospital | 1 | 1 | 1 | 2018 |
| University of Groningen | Academic/Hospital | 1 | 1 | 1 | 2017 |
| Yale University | Academic/Hospital | 1 | 1 | 1 | 2022 |
5 organizations
Page 1 / 1